Ellen Seely, MD
Endocrinology, Diabetes & Metabolism · Boston, MANPI 1407814023
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $40,357 of the $40,990 with a category attached, or 98.5%. 5 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 35.1% of the total. Reporting peaked in 2023 at $16,375 and has fallen 87.4% since, to $2,070 in 2025. Among endocrinology, diabetes & metabolism clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 20 payments — averaging $2049.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$14K
- Lexicon Pharmaceuticals, Inc.$9K
- Amarin Pharma, Inc.$8K
- Novo Nordisk$6K
- Roche Diagnostics Corporation$3K
Across 5 payments — averaging $1558.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Neurocrine Biosciences, Inc.$8K
What the payments were for
- Consulting fees$40,35798%
- Travel & lodging$5071%
- Food & beverage$940%
- Education$320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 4 | $14,403 |
| Lexicon Pharmaceuticals, Inc. | 1 | $9,429 |
| Amarin Pharma, Inc. | 11 | $8,351 |
| Novo Nordisk | 3 | $5,907 |
| Roche Diagnostics Corporation | 1 | $2,900 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Vascepa$8,133
- CD cobas Reagents$2,900
How this compares
$40,990 in reported general payments places this provider in the 90th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.
See all endocrinology, diabetes & metabolism providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 12 | $17,708 |
| SynthroidLevothyroxine Sodium | 13 | $1,723 |
| Irbesartan | 15 | $622 |
| Levothyroxine Sodium | 46 | $480 |
| Spironolactone | 11 | $151 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Boston
- Jason GagliaBoston$2.4M
- Vanita ArodaBoston$482K
- Michael RosenblattBoston$447K
- Steven RussellBoston$445K
- Beverly BillerBoston$346K
- Christos MantzorosBoston$243K
- Augusto Caballero-RoblesBoston$150K
- Osama HamdyBoston$117K
- Barbara KahnBoston$105K
- Naomi FisherBoston$79K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.